- Market Capitalization, $K 215,106
- Shares Outstanding, K 61,459
- Annual Sales, $ 77,450 K
- Annual Income, $ -202,120 K
- 60-Month Beta 1.91
- Price/Sales 2.75
- Price/Cash Flow N/A
- Price/Book 1.49
|Period||Period Low||Period High||Performance|
| || |
-0.53 (-12.50%)since 09/02/22
| || |
+0.66 (+21.64%)since 07/01/22
| || |
-16.56 (-81.70%)since 10/04/21
An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.
The average of price targets set by Wall Street analysts indicates a potential upside of 291% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive...
MGNX earnings call for the period ending June 30, 2022.
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by...
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing...
In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on MacroGenics (MGNX – Research Report), with a price target of $20.00. The company's shares closed last Monday...